Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease

被引:102
作者
Leidner, Andrew J. [1 ]
Chesson, Harrell W. [2 ]
Xu, Fujie [1 ]
Ward, John W. [1 ]
Spradling, Philip R. [1 ]
Holmberg, Scott D. [1 ]
机构
[1] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA
[2] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA
关键词
QUALITY-OF-LIFE; TREATMENT-NAIVE PATIENTS; VIRUS-INFECTION; UNITED-STATES; ANTIVIRAL THERAPY; VIRAL-HEPATITIS; FREE REGIMENS; IMPACT; HEALTH; COHORT;
D O I
10.1002/hep.27736
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
New treatments for hepatitis C virus (HCV) may be highly effective but are associated with substantial costs that may compel clinicians and patients to consider delaying treatment. This study investigated the cost-effectiveness of these treatments with a focus on patients in early stages of liver disease. We developed a state-transition (or Markov) model to calculate costs incurred and quality-adjusted life-years (QALYs) gained following HCV treatment, and we computed incremental cost-effectiveness ratios (cost per QALY gained, in 2012 US dollars) for treatment at different stages of liver disease versus delaying treatment until the subsequent liver disease stage. Our analysis did not include the potential treatment benefits associated with reduced non-liver-related mortality or preventing HCV transmission. All parameter values, particularly treatment cost, were varied in sensitivity analyses. The base case scenario represented a 55-year-old patient with genotype 1 HCV infection with a treatment cost of $100,000 and treatment effectiveness of 90%. In this scenario, for a 55-year-old patient with moderate liver fibrosis (Metavir stage F2), the cost-effectiveness of immediately initiating treatment at F2 (versus delaying treatment until F3) was $37,300/QALY. For patients immediately treated at F0 (versus delaying treatment until F1), the threshold of treatment costs that yielded $50,000/QALY and $100,000/QALY cost-effectiveness ratios were $22,200 and $42,400, respectively. Conclusion: Immediate treatment of HCV-infected patients with moderate and advanced fibrosis appears to be cost-effective, and immediate treatment of patients with minimal or no fibrosis can be cost-effective as well, particularly when lower treatment costs are assumed. (Hepatology 2015;61:1860-1869)
引用
收藏
页码:1860 / 1869
页数:10
相关论文
共 45 条
  • [1] American Association for the Study of Liver Diseases, 2014, REC TEST MAN TREAT H
  • [2] [Anonymous], COST EFFECTIVENESS I
  • [3] Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C
    Bennett, WG
    Inoue, Y
    Beck, JR
    Wong, JB
    Pauker, SG
    Davis, GL
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) : 855 - +
  • [4] Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients
    Bernstein, D
    Kleinman, L
    Barker, CM
    Revicki, DA
    Green, J
    [J]. HEPATOLOGY, 2002, 35 (03) : 704 - 708
  • [5] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [6] Hepatitis C treatment completion rates in routine clinical care
    Butt, Adeel A.
    McGinnis, Kathleen A.
    Skanderson, Melissa
    Justice, Amy C.
    [J]. LIVER INTERNATIONAL, 2010, 30 (02) : 240 - 250
  • [7] Health assessment for chronic HCV infection - Results of quality of life
    Carithers, RL
    Sugano, D
    Bayliss, M
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (12) : S75 - S80
  • [8] Psychological impact of chronic hepatitis C: Comparison with other stressful life events and chronic diseases
    Castera, Laurent
    Constant, Aymery
    Bernard, Pierre-Henri
    de Ledinghen, Victor
    Couzigou, Patrice
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (10) : 1545 - 1550
  • [9] Cost Effectiveness of Direct-Acting Antiviral Therapy for Treatment-Naive Patients With Chronic HCV Genotype 1 Infection in the Veterans Health Administration
    Chan, Kee
    Lai, Mai Ngan
    Groessl, Erik J.
    Hanchate, Amresh D.
    Wong, John B.
    Clark, Jack A.
    Asch, Steven M.
    Gifford, Allen L.
    Ho, Samuel B.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (11) : 1503 - 1510
  • [10] Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C
    Coffin, Phillip O.
    Scott, John D.
    Golden, Matthew R.
    Sullivan, Sean D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 54 (09) : 1259 - 1271